The Food and Drug Administration on Thursday announced the first round of experimental drugs that will receive drastically expedited reviews at the agency, part of an effort to prioritize medicines the Trump administration deems as “supporting U.S. national interests.”
The nine medicines announced by the FDA include potential treatments for vaping addiction, deafness, pancreatic cancer and other conditions.
